Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome

Neuroscience Letters

Volumn 260, Issue 2, 1999, Pages 141-145

  Lubec, Gert ^a   Labudova, Olga ^a   Cairns, Nigel ^b   Fountoulakis, Michael ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alzheimer's disease; Brain; Down's syndrome; Glyceraldehyde 3 phosphate dehydrogenase; Subtractive hybridization; Two dimensional gel electrophoresis

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; DOWN SYNDROME; ENZYME LOCALIZATION; FEMALE; GEL ELECTROPHORESIS; GLUCOSE METABOLISM; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

AGED; BRAIN; DOWN SYNDROME; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; MALE;

EID: 0033613767     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00952-5     Document Type: Article

References (20)

1. Alexander M.C., Lomanto M., Nasrin N., Ramaika C. Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through cis-acting DNA sequences. Proc. Natl. Acad. Sci. USA. 85:1988;5092-5097.
2. Anneren K.G., Korenberg J.R., Epstein C.J. Phosphofructokinase activity in fibroblasts aneuploid for chromosome 21. Human Genet. 76:1987;63-65.
3. Beutler, E., Red Cell Metabolism. A Manual of Biochemical Methods, 2nd edn., Grune and Stratton, NY, pp. 51-52.
4. Burger P.C., Vogel F.S. The development of pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am. J. Pathol. 73:1973;457-476.
5. Epstein, C.J., Down Syndrome (Trisomy 21). In Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. (Eds.), The Metabolic and Molecular Basis of Inherited Disease, McGraw Hill, New York, 1992, pp. 749-794.
6. Fountoulakis M., Langen H. Identification of proteins by matrix-assisted laser desorption ionization-mass spectroscopy following in-gel digestion in low -salt, nonvolatile buffer and simplified peptide recovery. Anal. Biochem. 250:1997;153-156.
7. Funabashi T., Brooks P.J., Weesner G.D., Pfaff D.W. Luteinizing hormone-releasing hormone receptor messenger ribonucleic acid expression in the rat pituitary during lactation and the estrous cycle. J. Neuroendocrinology. 6:1994;261-266.
8. Goldsworthy S.M., Goldsworthy T.L., Sprankle C.S., Butterworth B.E. Variation in expression of genes used for normalization of Northern blots after induction of cell proliferation. Cell Prolif. 26:1993;511-518.
9. Labudova O., Lubec G. cAMP upregulates the transposable element mys-1: a possible link between signaling and mobile DNA. Life Sci. 62:1998;431-437.
10. Langen H., Röder D., Juranville J.-F., Fountoulakis M. Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis. 18:1997;2085-2090.
11. Mirra S.S., Heyman A., McKeel D., Sumi S., Crain B.J. The consortium to establish a registry for Alzheimer disease (CERAD). II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
12. Nasrin N., Ercolani L., Denaro M., King X.F., Kang I., Alexander M. An insulin response element in the glyceraldehyde-3-phosphate dehydrogenase gene binds a nuclear protein induced by insulin in cultured cells and by nutritional manipulations in vivo. Proc. Natl. Acad. Sci. USA. 87:1990;5273-5278.
13. Pueschel, S.M., Sassamann, E.A., Scola, P.S., Thuline, H.C., Stark, A.M. and Horrobin, M., Biomedical aspects in Down syndrome. In Pueschel, S.M. and Rynders, J.E. (Eds.), Down Syndrome. Advances in Biomedicine and the Behavioral Sciences, Ware, Cambridge, MA, 1982, pp. 169.
14. Schapiro M.B., Grady C.L., Haxby J.V. Nature of mental retardation and dementia in Down's syndrome: study with PET. CT, and neuropsychology, Neurobiol. Aging. 13:1992;723-734.
15. Schmidt H.J., Schaum U., Pichotka J.P. The influence of mode and intensity of homogenization on the absolute value and stability of oxygen consumption of guinea pig liver homogenates. Z. Naturforsch. C. 32:1977;908-912.
16. Seidl R., Greber S., Schuller E., Bernert G., Cairns N., Lubec G. Evidence against increased oxidative DNA damage in Down Syndrome. Neurosci. Lett. 235:1997;137-140.
17. Tierney M.C., Fisher R.H., Lewis A.J., Torzitto M.L., Snow W.G., Reid D.W., Nieuwstraaten P., Van Rooijen L.A.A., Derks H.J.G.M., Van Wijk R., Bischop A. The NINCDA-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease. Neurology. 38:1988;359-364.
18. Van Keuren M., Drabkin H., Hart I., Patterson D., Vora S. Regional mapping of liver type 6 phosphofructokinase to 21q22.3. Am. J. Human Genet. 37:1985;20-26.
19. Vora S., Franke U. Assignment of the human gene for liver-type 6-phosphofructokinase isoenzyme (PFK-L) to chromosome 21 by using somatic cell hybrids and monoclonal anti-L-antibody. Proc. Natl. Acad. Sci. USA. 78:1981;3738-3742.
20. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:1985;278-282.